GSK investing additional L200M in U.K. manufacturing

GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) said it will invest about L200 million ($327.4 million) for manufacturing in the U.K. The pharma said it will build new manufacturing facilities at its Ware site as well as a new bulk sterile building and filing line at its Worthing site for the pharma's antibiotic Augmentin, a combination of amoxicillin and clavulanate, a beta lactamase (LACTB) inhibitor. GSK said it also will build a new center to develop practical manufacturing applications from emerging science and technologies. The pharma said it expects the investment to create 250 new jobs. ...